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Abstract The classical short-term effect (within minutes) of
arginine vasopressin (AVP) consists in increasing sodium,
chloride and water transport in kidney cells. More recently,
long-term actions (several hours) of the hormone have been
evidenced on water and sodium fluxes, due to transcriptional
enhancement in the expression of their transporters. The present
study demonstrates that AVP is also responsible for a long-term
increase in net chloride secretion. In the RCCD1 rat cortical
collecting duct cell line, 1038 M AVP induced, after several
hours, an increase in net 36Cl3 secretion. This delayed effect of
AVP was inhibited by basal addition of 1034 M bumetanide and
apical addition of 1034 M glibenclamide, suggesting chloride
entry at the basal membrane through a Na+/K+/2Cl3 and apical
secretion through a chloride conductance. An original acute cell
permeabilization method was developed to allow for entry of
antibodies directed against the regulatory region (R) of the cystic
fibrosis transmembrane regulator (CFTR) into the cells. This
procedure led to a complete and specific blocking of the long-
term net chloride secretion induced by AVP. Finally, it was
observed that CFTR transcripts steady-state level was signifi-
cantly increased by AVP treatment. Besides the well-documented
short-term effect of AVP on chloride transport, these results
provide evidence that in RCCD1 cells, AVP induces a delayed
increase in transepithelial net chloride secretion that is mediated
by a Na+/K+/2Cl3 co-transporter and CFTR.
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1. Introduction
In the kidney, short-term e¡ects of arginine vasopressin
(AVP) are well documented: AVP is mainly involved in the
regulation of water reabsorption, but also modulates sodium
and chloride transport [1,2]. These e¡ects are directly linked
to activation of adenylate cyclase and rapid cAMP produc-
tion. Recently, we have provided evidence for another mech-
anism which may be related to transcriptional e¡ects of AVP.
In this study [3], we showed that, in the rat cortical collecting
duct (CCD) cell line RCCD1, AVP leads to a delayed stim-
ulation of Na transport by increasing the de novo synthesis
of certain subunits of the epithelial sodium channel and of the
Na/K-ATPase. We hypothesized that this e¡ect is in turn
due to an e¡ect of the hormone on gene expression through
interaction of transcription factors on cAMP response ele-
ments. However, the stimulation of Na reabsorption did
not fully account for the long-term AVP-induced increase in
ionic transport. Indeed, the delayed increase in short-circuit
current observed after AVP treatment was only partially in-
hibited by the sodium channel blocker amiloride [3]. There-
fore, we decided to search for another transport system up-
regulated by AVP. Since it has been shown that cAMP indu-
ces a short-term increase in net chloride secretion in several
cellular models of the CCD [4^7], we decided to examine
whether AVP could also exert long-term e¡ects on chloride
transport.
In this study, evidence is provided that AVP induces a
delayed stimulation of net chloride secretion in RCCD1 cells,
which is blocked by inhibitors of Na/K/2Cl3 and chloride
channels, presumably cystic ¢brosis transmembrane regulator
(CFTR). Moreover, acute permeabilization of cells in the
presence of an antibody (Ab) against CFTR prevented the
AVP-induced net chloride secretion. Altogether, these results
favor the view that AVP promotes a delayed increase in net
chloride transepithelial secretion mediated by basal Na/K/
2Cl3 transporters and apical CFTR channels. Moreover, this
e¡ect is likely to involve an increase in the steady-state levels
of CFTR mRNA.
2. Materials and methods
2.1. Cell culture
Experiments were performed on the RCCD1 rat CCD cell line [8],
between passages 24 and 42. Cells were grown on permeable supports
coated with collagen (type 1 from rat tail, Institut Jacques Boy,
France). The culture medium (2% fetal bovine serum (FBS)-DM)
was as follows: HAM’s F12:DMEM 1:1, NaHCO3 14 mM, gluta-
mine 2 mM, dexamethasone 5U1038 M, sodium selenite 3U1038 M,
transferrin 5 Wg/ml, insulin 5 Wg/ml, EGF 10 Wg/ml, T3 5U1038 M,
penicillin-streptomycin 10 U/ml, HEPES 20 mM, pH 7.4, FBS 2%
(Gibco, Les Ulis, France). When cell con£uence was reached (3^4
days after seeding), cells were incubated overnight in a minimum
medium (MM: HAM’s F12:DMEM 1:1, NaHCO3 14 mM, gluta-
mine 2 mM, penicillin-streptomycin 10 U/ml, HEPES 20 mM, pH
7.4) before treatment with 1038 M AVP on the basal side.
2.2. 36Cl3 transport studies
Transepithelial 36Cl3 transport was determined across RCCD1 cells
cultured on 12 mm transwell ¢lters (Costar). Both the apical to basal
and the basal to apical £uxes were determined by adding 100 nCi/ml
36Cl3 (Amersham, 89 WCi/ml) as a tracer at the apical side or at the
basal side of the cells, allowing for determination of unidirectional
chloride £uxes and subsequent calculation of net £uxes. After 10
min of incubation at 37‡C, the medium was collected at the opposite
side. Radioactivity was counted using a L-scintillation counter (Wal-
lak, Pharmacia) and results were expressed in nmol/10 min/cm2. In
some experiments, cells were pre-incubated with bumetanide 1034 M
(Sigma) dissolved in 0.1% ethanol or glibenclamide 1034 M (Calbio-
chem) dissolved in 0.1% DMSO in the apical or basal medium before
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determination of 36Cl3 £uxes. Finally, some experiments were per-
formed using a MM without bicarbonate (HAM’s F12:DMEM
HCO33 -free, glutamine 2 mM, penicillin-streptomycin 10 U/ml,
HEPES 20 mM, pH 7.4) to examine the in£uence of Cl3/HCO33 ex-
changer in the phenomenon.
2.3. Permeabilization procedure
In series of experiments, cells were permeabilized in order to give
access of the HCF703 Ab directed against the regulatory region (R) of
CFTR [9,10] to its intracellular epitope before 36Cl3 transport experi-
ments. In these experiments, cells grown on 12 mm diameter transwell
¢lters were incubated overnight in MM before treatment or not with
1038 M AVP. After 4.5 h of treatment with or without AVP, the
basolateral medium (1.5 ml) was maintained but the apical medium
was replaced with the same volume (0.5 ml) of MM to which anti-
CFTR Abs (1/4000) were added, in the absence or presence of the
immunizing peptide (1.2 Wg/ml stock in distilled water). The sequence
of this peptide is NPINSIRKFS [9]. Multiwell dishes containing the
¢lters were then deposed on a bath of ethanol previously cooled at
320‡C by addition of dry ice. Under these conditions, cell freezing
occurred within 10^15 min. Just after freezing, dishes were put back at
37‡C in the incubator to allow for thawing. This procedure was de-
signed to entry of the Ab and subsequent sealing of the apical mem-
brane, thus permitting for further evaluation of its e¡ect on transport
properties of the epithelium. 36Cl3 transport experiments were per-
formed at 7.5 h as previously described. In preliminary experiments
performed with trypan blue (data not shown), it was observed that
s 95% of the cells were permeabilized with this method. As a control,
permeabilization was performed in the presence of a monoclonal anti-
L-actin Ab (1/4000) (Sigma) which belongs to the same IgG isotype
(mouse IgG1 isotype) as the anti-CFTR Ab used in this study.
2.4. Electron microscopy
Three hours after the permeabilization procedure (i.e. 7.5 h after
AVP treatment), cells were immediately ¢xed in 2.5% glutaraldehyde
in PBS at room temperature, then post-¢xed in 1% osmium tetroxide
and embedded in Epon. Ultrathin sections were performed on trans-
versally oriented monolayers and examined with a Philips EM 410
electron microscope. Morphological features of permeabilized cells
were compared to those of non-permeabilized ones.
2.5. RNAse protection assay
A RNAse protection assay was performed on RCCD1 cells grown
on 24 mm transwell ¢lters (Costar) and lysed with a guanidium thi-
ocyanate solution (guanidium thiocyanate 4 M, Na citrate 25 mM,
pH 7, sarcosyl 0.5%, L-mercaptoethanol 0.1 M). The protocol was as
previously described [11]. Part of the rat CFTR cDNA (exon 10^13)
subcloned into Bluescript was used to synthesize CFTR cRNA probe
[12,13] (cRNA probe: 689 bp, protected fragment: 500 bp). L-Actin
probe was synthesized using a cDNA inserted in a Bluescript plasmid
[11] (cRNA probe: 158 bp). The L-actin mRNA signal was used as an
internal standard to take into account the di¡erences in gel loading.
Antisense cRNA probes were synthesized with [32P]UTP (15 TBq/
mmol, Amersham, UK) using the Promega riboprobe kit. Gels were
exposed to Kodak XOMAT AR 5 ¢lms. Signal quanti¢cation was
performed using an image analyzer (Optilab, Graftek, Grenoble,
France) and for each condition, results were normalized to the signal
obtained with L-actin. To illustrate the e¡ects of AVP, normalized
levels of CFTR mRNA are provided as relative to the control levels
without AVP.
2.6. Statistical analysis
Results are expressed as mean values þ S.E.M. Student’s t test for
unpaired data and variance analyses was performed (when allowed by
the F value, results were compared by the modi¢ed least signi¢cant
di¡erence).
3. Results
3.1. E¡ect of AVP on transepithelial Cl3 transport: short-term
and long-term responses
The e¡ect of AVP on net chloride secretion was examined
by 36Cl3 £uxes experiments after 10 min, 4 and 7.5 h of treat-
ment with the hormone (Fig. 1). Fig. 1A is an example of an
experiment realized under control conditions and after 7.5 h
of AVP treatment. Both apical to basal (absorptive) and basal
to apical (secretory) £uxes were evidenced, allowing for deter-
mination of the net £ux. Under control conditions, a weak,
non-signi¢cant, net chloride secretion was observed. Treat-
ment of RCCD1 cells for 7.5 h with 1038 M AVP did not
modify the absorptive 36Cl3 £ux but, in contrast, it signi¢-
cantly increased the secretory one, leading to a signi¢cant
increase in net chloride secretion. Fig. 1B is the time-course
of the AVP e¡ect on chloride transport. Ten minutes of treat-
ment with AVP resulted in a large increase in net chloride
secretion, corresponding to the known short-term e¡ect of
the hormone. Four hours after AVP addition, no di¡erence
could be observed between the control and the AVP-treated
cells, suggesting down-regulation of the short-term e¡ect.
After 7.5 h of AVP, net chloride secretion was clearly in-
creased.
3.2. Long-term AVP-induced net chloride secretion involves a
basal Na+/K+/2Cl3 and an apical chloride conductance
To determine which ionic transporters were potentially in-
volved in the long-term net chloride secretion, we tested the
e¡ect of the Na/K/2Cl3 blocker bumetanide [14] and of the
CFTR-like Cl3 conductance inhibitor glibenclamide [15]. In
addition, experiments were performed in a medium devoid of
bicarbonate to block the activity of the Cl3/HCO33 exchanger.
Fig. 1. Long-term e¡ect of AVP on net transepithelial chloride
transport in RCCD1 cells. A: The e¡ect of AVP 1038 M was tested
on the apical to basal (ABSORPTION) and the basal to apical (SE-
CRETION) 36Cl3 £uxes. Cells were incubated for 7.5 h in the pres-
ence of 1038 M AVP (AVP) or under control conditions (Control)
before determination of the 36Cl3 £uxes. Each bar is the mean val-
ue of three ¢lters. *, ***: P6 0.05, P6 0.001, AVP vs. Control. B:
The time-course of the AVP e¡ect was determined on the net trans-
epithelial 36Cl3 secretion by incubating cells for di¡erent times (10
min, 4 and 7.5 h) with (AVP) or without (Control) the hormone.
Each bar is the mean value of 12^15 ¢lters from ¢ve experiments.
***: P6 0.001, AVP vs. Control.
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Results are given in Fig. 2. As compared to control experi-
ments (performed in the presence of the diluent only), addi-
tion of 1034 M bumetanide on the basal side of the cells
signi¢cantly reduced both the basal level of net chloride se-
cretion and blocked completely the long-term response to
AVP. In contrast, apical addition of 1034 M bumetanide
did not prevent the AVP-induced net chloride secretion. Ap-
ical addition of 1034 M glibenclamide also totally blocked the
long-term AVP-induced net chloride secretion, without a sig-
ni¢cant e¡ect on the basal secretion. Finally, when experi-
ments were performed in a medium devoid of bicarbonate,
the e¡ect of 7.5 h of treatment with AVP was not signi¢cantly
di¡erent from that observed in a medium containing bicar-
bonate. Altogether, these experiments suggest that the long-
term AVP-induced net chloride secretion may involve an entry
of chloride at the basal membrane through a Na/K/Cl3 co-
transporter and chloride exit at the apical membrane through
a glibenclamide-sensitive chloride conductance. The Cl3/
HCO33 exchanger does not appear to be involved in the phe-
nomenon.
3.3. Putative role of CFTR in the delayed AVP-induced
increase in net chloride secretion
Since glibenclamide is not a highly speci¢c inhibitor of
CFTR but inhibits also K channels [16], experiments were
designed to test whether the HCF703 anti-CFTR Ab [9,10]
was able to block the long-term AVP e¡ect on chloride trans-
port. Indeed, such blocking properties have been described for
anti-CFTR Abs directed against the regulatory region (R)
[17]. As the epitope recognized by anti-CFTR Ab is intracel-
lular, it was necessary to design an experiment that allows for
cell entry of the Ab and subsequent resealing of the apical
membrane before carrying out the transport experiments. Free
access of the Abs to the R region of CFTR was yielded by cell
permeabilization as described in Section 2 (When cells were
not permeabilized, anti-CFTR Ab did not block net chloride
secretion.) Examination of the ultrastructural characteristics
of permeabilized cells by electronic microscopy revealed no
major modi¢cation of the cellular aspect as compared to in-
tact cells (Fig. 3A,B). Results of 36Cl3 transport are shown in
Fig. 3C. As in non-permeabilized cells, treatment of permea-
bilized RCCD1 cells for 7.5 h with AVP resulted in a large
increase in net 36Cl3 secretion. Under these conditions, addi-
tion of anti-CFTR Ab totally blocked the AVP e¡ect on net
chloride secretion. Conversely, the e¡ect of AVP was observed
when the permeabilization was performed in the presence of
the anti-CFTR Ab and an excess of immunizing peptide. Fi-
nally, when experiments were performed using another unre-
lated Ab of the same isotype (anti-L-actin Ab), the AVP e¡ect
on net chloride secretion was not inhibited. These data suggest
that CFTR is involved in chloride transport in RCCD1 cells
and that CFTR plays a major role in the long-term e¡ect of
AVP on net chloride secretion.
3.4. AVP increases CFTR mRNAs accumulation
The e¡ect of 1038 M AVP was evaluated on the accumu-
lation of mRNA encoding CFTR by a RNAse protection
assay (Fig. 4). An example of a RNAse protection assay is
shown in Fig. 4A. A protected band of an expected size (500
nucleotides) was detected in control RCCD1 cells and its ex-
pression was increased 7.5 h after AVP addition. Smaller
bands were also present but without apparent correlation
with CFTR mRNA expression. Quanti¢cation of results (ra-
dioactivity of the 500 nucleotides band, normalized to the
Fig. 2. E¡ect of bumetanide, glibenclamide and absence of bicar-
bonate on the long-term AVP-induced net chloride secretion. The
e¡ect of 1034 M bumetanide and 1034 M glibenclamide added ei-
ther apically or basally was tested on the AVP-induced net chloride
secretion at 7.5 h. Basal (B) addition of bumetanide blocked the
AVP e¡ect whereas apical addition (Ap) of the drug did not modify
it. Conversely, apical but not basal addition of glibenclamide
blocked the long-term e¡ect of AVP. Finally, replacing the medium
with a HCO33 -free medium did not prevent the long-term AVP-in-
duced net chloride secretion. Each bar represents the mean value of
9^12 ¢lters from ¢ve experiments. **, ***: P6 0.01, P6 0.001, ex-
perimental vs. control without AVP.
Fig. 3. E¡ect of anti-CFTR Ab on the AVP-induced increase in net
36Cl3 secretion. The e¡ect of anti-CFTR Abs directed against the
regulatory region (R) was tested on 36Cl3 secretion after the cell
permeabilization procedure (see Section 2). A and B illustrate the
ultrastructural aspect of RCCD1 cells in the absence (A) or presence
(B) of the permeabilization procedure. No major alteration of the
cell structure was observed. The increase in 36Cl3 secretion observed
after 7.5 h of incubation with AVP was blocked by pre-incubating
cells with the anti-R CFTR Ab (1/4000) after cell permeabilization
(see Section 2). Anti-CFTR Ab was added after 4.5 h of treatment
with AVP. The blocking e¡ect of the Ab was signi¢cantly impaired
in the presence of an excess of the immunizing peptide (peptide). It
was not reproduced by another Ab from the same isotype (anti-L-
actin Ab; 1/4000: control Ab). Each bar is the mean value of 9^12
¢lters from six experiments. **, ***: P6 0.01, P6 0.001, AVP 7.5 h
vs. Control.
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actin signal) allows us to examine CFTR mRNA levels in cells
treated for various delays with 1038 M AVP, as compared to
untreated cells. A signi¢cantly increased level of CFTR tran-
scripts was observed 1 h after the addition of 1038 M AVP.
The mRNA levels then remained stable up to 7.5 h (Fig. 4B).
4. Discussion
The polypeptide hormone AVP is known to act in the renal
collecting duct to promote water and sodium reabsorption
[1,2]. This e¡ect is rapid (few minutes) and involves binding
to V2 membrane receptors and cAMP cascade activation.
More recently, it has been shown that AVP also modulates
chloride transport, although the orientation of the net £ux
(absorptive versus secretory) appears to vary according to
the experimental models. In some cases, it was reported that
AVP addition results in net chloride reabsorption [18^20].
Other reports document a net chloride secretion in the termi-
nal portions of the nephron [21^24], which is stimulated by
cAMP [25^27]. In the amphibian A6 cell line (a model of the
distal nephron), Chalfant et al. [4] showed that AVP promotes
both net chloride secretion and sodium reabsorption. Yanase
and Handler also showed that adenosine 3P,5P-cyclic mono-
phosphate stimulates net chloride secretion in this epithelium
[5]. Morris et al. [6] recently reported that AVP stimulates Cl3
secretion in A6 cells. Stimulation of net chloride secretion by
AVP was also demonstrated in Madin-Darby canine renal
cells (MDCK), another model of the distal nephron [7]. Ac-
tually, since the electrochemical driving force for Cl3 across
the apical membrane is approximately zero under basal con-
ditions [28], the reabsorption or, conversely, the secretion of
chloride may largely depend on hormonal stimulation as well
as on the cell’s ionic context. The nature of the chloride trans-
porters involved in the AVP e¡ect remains under discussion.
There are several arguments in favor of the involvement of the
CFTR in chloride movements. Although the precise role of
CFTR in the kidney is largely unknown, several studies have
shown that CFTR is expressed in this organ and in particular
in the collecting duct [29^31]. In primary cultures of rabbit
cortical collecting duct (CCD), E. Nagy et al. speculated that
AVP could rapidly (6 10 min) increase Cl3 transport through
CFTR Cl3 channels [18]. In the M1 mouse CCD cell line,
Letz and Korbmacher [32] demonstrated that forskolin was
able to stimulate an apical Cl3 conductance and suggested
that the stimulated channels were CFTR-like Cl3 channels.
In the inner medullary collecting duct, both Husted et al. [25]
and Vandorpe et al. [26] presented evidence for an involve-
ment of CFTR in anion secretion in response to cAMP. Fi-
nally, Moyer et al. demonstrated that cAMP stimulates
CFTR-mediated Cl3 secretion in MDCK cells by activating
channels resident in the apical membrane [33]. Our results also
report a short-term e¡ect of AVP on net chloride secretion in
the RCCD1 cell line.
In addition to this short-term action, evidence has been
provided for long-term e¡ects of AVP. Indeed, it appears
now that the cascade of events linked to cAMP generation
involves a series of complex processes a¡ecting cAMP-respon-
sive transcription factors which lead to regulation of gene
expression. cAMP-dependent proteins (CREB, CREM,
ATF1) have been shown to bind to speci¢c cAMP-responsive
elements (CRE) located in the promoter region of several
genes [34]. Such a transcriptional regulatory pathway may
well be implicated in the physiological action of AVP, since
expression of some transporters and channels has been shown
to depend on AVP. This results in delayed and sustained
modi¢cations in transport events. Long-term increase in the
expression of the water channel AQP2 has been reported to
occur after AVP treatment or dehydration [35,36]. Similarly,
we have shown, in a previous study, that sodium reabsorption
was increased several hours after AVP exposure in the
RCCD1 renal cell line [3]. This late e¡ect of AVP was pre-
ceded by de novo synthesis of L- and Q-subunits of the ami-
loride-sensitive epithelial sodium channel ENaC and of the K1
subunit of Na/K-ATPase.
The goal of the present study was to examine whether AVP
could also exert a long-term e¡ect on net chloride secretion.
We have previously reported [3] that the delayed increase in
ion transport induced by AVP was only partially sensitive to
amiloride, suggesting that besides sodium transport, another
pathway was concerned. Evidence is provided in the present
report that AVP promotes a delayed stimulation of net chlo-
ride secretion in RCCD1 cells. This increased net chloride se-
cretion appears to occur through a basal Na/K/2Cl3 co-
Fig. 4. E¡ect of AVP on the amount of mRNA encoding CFTR.
The amount of mRNA encoding CFTR was determined by a
RNAse protection assay. A: First lane: hybridization of CFTR and
actin probes with yeast tRNA. Second and third lanes: probes en-
coding L-actin and CFTR. MW: molecular weight markers. Lanes 5
and 6: hybridization of CFTR and actin probes with lysates of
cells, treated (AVP) or not (Control) with AVP for 7.5 h; protected
fragments are indicated by arrows. B gives the kinetics of the in-
crease in CFTR mRNA in response to AVP. Each point is the
mean value of 5^7 determinations. *, **: P6 0.05, P6 0.01 AVP
vs. Control.
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transporter and, likely, the apical CFTR. Indeed, it is blocked
by basal addition of bumetanide and apical administration of
glibenclamide. In addition, an Ab raised against the regula-
tory region (R) of CFTR can block net chloride secretion in
these cells, suggesting that CFTR is indeed important in the
described chloride secretory pathway. Moreover, an increase
in the steady-state level of CFTR mRNA appears to precede
the increase in chloride transport. The Na/K/2Cl3 appears
to be a major component of chloride entry into the cells in a
variety of epithelia which secrete chloride [37]. In RCCD1
cells, one might speculate that it corresponds to the secretory
form of the Na/K/2Cl3 (BSC2) which is expressed in the
basolateral membrane of cells from the rat collecting duct
[38,39]. Interestingly, it has been reported that in intestinal
HT29 cells, cAMP was able to stimulate net chloride secretion
at both short- (minutes) and long-term (8 h) [40]. Authors
showed that the long-term secretion involved basal Na/K/
2Cl3 and apical CFTR and that it was mediated by an in-
crease in the CFTR copy number at the mRNA level and de
novo protein synthesis. In our study, we also observed an
increase in the amount of mRNA encoding the CFTR.
Thus, similar transport systems and regulatory pathways ap-
pear to be involved, although in two di¡erent epithelia. In
particular, CFTR appears to play a major role in this chloride
secretion mechanism. Interestingly, the CFTR mRNA level
was already increased near maximal after 1 h of AVP treat-
ment, whereas the physiological e¡ect on chloride secretion
was apparent only after several hours. It can be inferred
that the increase in CFTR expression is not the limiting factor
for the AVP-induced increase in Cl3 secretion. Indeed, one
can speculate that the basolateral entry through the Na/K/
2Cl3 could be rate limiting. Alternatively, since AVP concom-
itantly increases sodium entry through the apical sodium
channel (ENaC) [3], thus decreasing the driving force for ap-
ical Cl3 secretion, other transport pathways (as K or H
secretion) may be involved in this mechanism to allow for
chloride secretion. As a second hypothesis, one can propose
that, even if the increase in the CFTR mRNA level is a rapid
event, the following steps leading to an e¡ective increase in
chloride transport, i.e. mRNA maturation, protein transla-
tion, post-transcriptional events and CFTR expression in an
active form in the membrane, require some delay. Along this
line, such delay was observed between the AVP-induced in-
crease in the steady-state level of mRNA encoding the L- and
Q-subunits of ENaC and K1 subunit of the Na/K-ATPase
(1^3 h) and the observed e¡ect on Na reabsorption (6^7 h)
[3]. In particular, the number of ENaC present in the apical
membrane of the cells was not modi¢ed 4 h after AVP treat-
ment, but was signi¢cantly increased after 7.5 h [3].
Interestingly, CRE sequences have been identi¢ed in the
promoter region of CFTR [41,42]. But surprisingly, limited
information is available in the literature on transcriptional
regulation of CFTR. Based on promoter sequence analysis
and on CFTR transfection in di¡erent cell types, evidence
has been provided that both cAMP and the tumor-promoting
agent phorbol myristate acetate (PMA) in£uence CFTR tran-
script levels [41,43^45]. While PMA appears to down-regulate
these transcripts in T84 colonic cells [45], cAMP, acting
through PKA, is a positive regulator of CFTR gene expres-
sion [43]. Our experiments extend these ¢ndings to the re-
sponse to AVP, a peptide hormone with an important regu-
latory role in the kidney.
Together, the present ¢ndings suggest that AVP exerts a
delayed control of chloride transport in CCD cells, in addition
to its short-term e¡ect. Here, we provide evidence that expo-
sure of RCCD1 cells to AVP leads after several hours to an
increase in net chloride secretion and that this e¡ect might
involve CFTR. It will be of major interest to elucidate pre-
cisely the molecular events producing these e¡ects.
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